Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-26-060382
Filing Date
2026-05-13
Accepted
2026-05-13 17:20:48
Documents
76
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q capr-20260331x10q.htm   iXBRL 10-Q 1600328
2 EX-31.1 capr-20260331xex31d1.htm EX-31.1 10495
3 EX-31.2 capr-20260331xex31d2.htm EX-31.2 10230
4 EX-32.1 capr-20260331xex32d1.htm EX-32.1 5757
5 EX-32.2 capr-20260331xex32d2.htm EX-32.2 5745
  Complete submission text file 0001104659-26-060382.txt   7558609

Data Files

Seq Description Document Type Size
6 EX-101.SCH capr-20260331.xsd EX-101.SCH 62103
7 EX-101.CAL capr-20260331_cal.xml EX-101.CAL 58726
8 EX-101.DEF capr-20260331_def.xml EX-101.DEF 220886
9 EX-101.LAB capr-20260331_lab.xml EX-101.LAB 444278
10 EX-101.PRE capr-20260331_pre.xml EX-101.PRE 372044
80 EXTRACTED XBRL INSTANCE DOCUMENT capr-20260331x10q_htm.xml XML 1298951
Mailing Address 10865 ROAD TO THE CURE SUITE 150 SAN DIEGO CA 92121
Business Address 10865 ROAD TO THE CURE SUITE 150 SAN DIEGO CA 92121 (310) 358-3200
CAPRICOR THERAPEUTICS, INC. (Filer) CIK: 0001133869 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34058 | Film No.: 26974668
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)